Common Pharmacovigilance Inspection Failures

Introduction

Many pharmacovigilance professionals assume inspection findings arise from isolated mistakes.

In reality, inspectors often identify findings because they uncover broader weaknesses within the pharmacovigilance system.

Examples include:

• Weak governance
• Poor oversight
• Inadequate escalation
• Ineffective CAPAs
• Lack of organisational learning

A useful principle is:

Inspectors rarely focus only on what went wrong. They focus on why it was allowed to go wrong.

Understanding recurring inspection failures helps organisations strengthen readiness and reduce regulatory risk.

Failure 1: Poor PSMF Maintenance

The Pharmacovigilance System Master File is frequently one of the first documents reviewed.

Common issues include:

• Outdated organisational structures
• Missing vendors
• Incorrect responsibilities
• Inaccurate system descriptions
• Incomplete annexes

These deficiencies create concerns regarding system visibility and governance.

Why It Matters

Inspectors often use the PSMF as a roadmap for the inspection.

If the roadmap is inaccurate, confidence may decrease rapidly.

Prevention

• Scheduled reviews
• Change-control integration
• Periodic reconciliation

For additional discussion see:

[[what-is-a-psmf]]

[[psmf-qppv-oversight]]

Failure 2: Limited QPPV Oversight

A recurring inspection theme is insufficient visibility at QPPV level.

Examples include:

• Poor understanding of critical vendors
• Limited awareness of major risks
• Weak visibility of CAPAs
• Limited awareness of audit outcomes

Why It Matters

Inspectors frequently evaluate whether the QPPV maintains effective oversight.

Prevention

• Structured governance reporting
• Escalation frameworks
• Risk dashboards

For additional discussion see:

[[qppv-and-audit-oversight]]

[[vendor-oversight-for-qppvs]]

Failure 3: Weak Vendor Oversight

Outsourcing remains a significant inspection focus.

Common deficiencies include:

• Outdated SDEAs
• Missing audits
• Weak performance monitoring
• Poor vendor inventories
• Unclear responsibilities

Why It Matters

Outsourcing activities does not transfer responsibility.

Prevention

• Risk-based oversight
• Vendor audits
• Governance reviews

For additional discussion see:

[[vendor-risk-assessment]]

[[critical-vendor-management]]

Failure 4: Documentation-Reality Gaps

A classic inspection problem occurs when:

Documentation says one thing.

Operational practice shows something different.

Examples include:

• SOPs not followed
• Escalation processes not functioning
• Governance meetings not occurring
• Metrics not reviewed

Why It Matters

Inspectors place significant emphasis on operational evidence.

Prevention

• Periodic process verification
• Internal audits
• Management reviews

Failure 5: Weak Audit Programmes

Audit programmes are intended to provide assurance.

Recurring weaknesses include:

• Limited audit coverage
• Weak risk assessment
• Lack of independence
• Repeat findings
• Poor follow-up

Why It Matters

Weak audits reduce organisational visibility regarding risk.

Prevention

• Risk-based planning
• Independent auditing
• Effective CAPA governance

For additional discussion see:

[[pharmacovigilance-audits]]

Failure 6: Poor CAPA Effectiveness

Many organisations generate CAPAs.

Fewer implement effective CAPAs.

Common issues include:

• Weak root cause analysis
• Generic training actions
• Overdue actions
• Repeat deficiencies

Why It Matters

Repeat findings often indicate CAPA failure.

Prevention

• Strong root cause analysis
• Effectiveness verification
• Governance oversight

For additional discussion see:

[[audit-capas]]

[[inspection-capas]]

Failure 7: Weak Governance

Governance failures frequently sit behind inspection findings.

Examples include:

• Undefined responsibilities
• Poor escalation pathways
• Infrequent oversight meetings
• Limited management visibility

Why It Matters

Inspectors often evaluate whether risks remain visible and manageable.

Prevention

• Governance frameworks
• Defined ownership
• Routine reviews

Failure 8: Poor Risk Management

Some organisations struggle to identify and prioritise risk.

Examples include:

• Lack of risk assessments
• Outdated risk reviews
• Equal treatment of all activities

Why It Matters

Resources may be directed away from high-risk areas.

Prevention

• Formal risk assessment processes
• Risk-based planning
• Periodic reassessment

Failure 9: Data Integrity Weaknesses

As pharmacovigilance systems become increasingly digital, data integrity attracts growing attention.

Examples include:

• Missing records
• Inconsistent data
• Inadequate audit trails
• Weak access controls

Why It Matters

Inspectors must have confidence in safety data.

Prevention

• System validation
• Access management
• Data quality controls

Failure 10: Training Deficiencies

Training findings often reflect broader problems.

Examples include:

• Missing training records
• Incomplete training
• Training not linked to responsibilities

Why It Matters

Personnel must understand their roles.

Prevention

• Role-based curricula
• Periodic review
• Training effectiveness assessment

Failure 11: Weak Inspection Readiness

Many organisations prepare only after receiving notification.

Consequences may include:

• Document retrieval problems
• Inconsistent responses
• Resource disruption

Why It Matters

Preparation under pressure often exposes hidden weaknesses.

Prevention

• Continuous readiness
• Mock inspections
• Routine reviews

For additional discussion see:

[[inspection-readiness]]

Failure 12: Lack of Organisational Learning

Perhaps the most important failure is failure to learn.

Examples include:

• Repeat inspection findings
• Repeat audit findings
• Recurring CAPA themes
• Persistent governance weaknesses

Why It Matters

Inspectors expect evidence of improvement over time.

Prevention

• Trend analysis
• Management review
• Continuous improvement programmes

What Inspectors Are Really Assessing

Although findings may appear diverse, many relate to a small number of fundamental questions.

Visibility

Does the organisation understand its pharmacovigilance system?

Accountability

Are responsibilities clear?

Control

Can compliance be demonstrated?

Oversight

Are risks visible?

Improvement

Does the organisation learn from problems?

Most inspection findings ultimately connect to one or more of these themes.

Characteristics of Inspection-Ready Organisations

High-performing organisations typically demonstrate:

Strong PSMF Governance

Effective QPPV Oversight

Robust Vendor Management

Risk-Based Auditing

Effective CAPAs

Accurate Documentation

Strong Governance

Continuous Improvement

These characteristics support sustainable inspection readiness.

Key Takeaways

• Most inspection findings reflect systemic weaknesses rather than isolated errors.
• PSMF maintenance, QPPV oversight and vendor governance remain common inspection themes.
• Documentation must reflect operational reality.
• CAPA effectiveness is frequently scrutinised.
• Risk management and governance strongly influence inspection outcomes.
• Data integrity receives increasing attention.
• Inspection readiness should be continuous.
• Organisations that learn from findings generally perform better during future inspections.

References

1. EMA Good Pharmacovigilance Practices (GVP) Module III – Pharmacovigilance Inspections.
2. EMA Good Pharmacovigilance Practices (GVP) Module I – Pharmacovigilance Systems and Their Quality Systems.
3. EMA Good Pharmacovigilance Practices (GVP) Module II – Pharmacovigilance System Master File.
4. EMA Good Pharmacovigilance Practices (GVP) Module IV – Pharmacovigilance Audits.
5. Regulation (EC) No 726/2004.
6. Directive 2001/83/EC.
7. Commission Implementing Regulation (EU) No 520/2012.
8. ICH Q9 Quality Risk Management.
9. ICH Q10 Pharmaceutical Quality System.
10. PIC/S Guidance on Pharmacovigilance Inspections.